Vesely D L, Overton R M, McCormick M T, Schocken D D
Department of Medicine, J.A. Haley Veterans Hospital, Tampa, FL 33612, USA.
Metabolism. 1997 Jul;46(7):818-25. doi: 10.1016/s0026-0495(97)90129-3.
Long-acting natriuretic peptide (LANP), vessel dilator, and atrial natriuretic factor (ANF) (each infused at 100 ng/kg body weight [BW].min for 60 minutes) increased the circulating concentration of calcitonin gene-related peptide (CGRP) threefold to fourfold in 30 healthy humans. Within 30 minutes of stopping ANF infusion, the CGRP circulating concentration had returned to preinfusion levels, whereas its increase secondary to the other atrial peptides was still significant 2 to 3 hours after cessation of their infusions. There was a 50% decreased excretion (P < .001) of CGRP into the urine secondary to LANP and vessel dilator, which correlated with the increase of CGRP in the circulation. The ANF-induced 50% decreased CGRP excretion occurred after the circulating concentration of CGRP had returned to preinfusion levels. Kaliuretic peptide did not affect CGRP circulating concentration or excretion into urine. These data suggest that LANP and vessel dilator inhibit the metabolic breakdown of CGRP as part of their mechanism of increasing CGRP in plasma, whereas the ANF effect of increasing CGRP in plasma appears to be secondary to stimulating the release of CGRP.
长效利钠肽（LANP）、血管扩张剂和心房利钠因子（ANF）（均以100纳克/千克体重·分钟的剂量输注60分钟）可使30名健康人的降钙素基因相关肽（CGRP）循环浓度增加3至4倍。在停止ANF输注后30分钟内，CGRP循环浓度已恢复到输注前水平，而在停止输注其他心房肽2至3小时后，其导致的CGRP升高仍很显著。LANP和血管扩张剂使CGRP尿排泄减少50%（P<0.001），这与循环中CGRP的增加相关。ANF导致CGRP排泄减少50%发生在CGRP循环浓度恢复到输注前水平之后。利钾肽不影响CGRP循环浓度或尿排泄。这些数据表明，LANP和血管扩张剂抑制CGRP的代谢分解，这是它们增加血浆中CGRP机制的一部分，而ANF增加血浆中CGRP的作用似乎继发于刺激CGRP的释放。
